Under the terms of the agreement, XOMA will receive milestone payments from Rezolute related to financing, clinical development, regulatory progress and commercial sales and high single-digit to mid-teens royalties. XOMA will also receive $5M in Rezolute common stock and an additional $13M in cash and stock when Rezolute completes certain financing milestones.
Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities.
XOMA is entitled to receive low single-digit royalties on net sales of AB101 and other products developed from Rezolute's extended-release and oral plasma kallikrein inhibitor platforms.
XOMA 358 is a fully human antibody that inhibits the effect of elevated insulin by modulating the insulin receptor. It has Orphan Drug status in the U.S. and Europe for congenital hyperinsulinism.
Subscribe for full text news in your inbox